Genentech, Constellation Enter Largest Epigenetics Tie-Up Yet
This article was originally published in The Pink Sheet Daily
For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.
You may also be interested in...
Third Rock Ventures has raised $1.3 billion by going all-in on early-stage biotech with a homegrown company strategy that requires that its own people run many of its portfolio companies after launch. It’s hard to say definitively that the strategy is working, but then again, its investors just re-upped for a new half-billion-dollar fund.
The early-stage biotech venture firm drew its largest fund yet, topping $1 billion raised since inception, despite notching only two exits from its first two funds.
Epigenetics, an area of biology replete with interesting novel targets and potential for developing drugs that overcome cancer resistance, is a popular topic this year at the American Association for Cancer Research annual meeting, in Washington, D.C., April 6-10.